Measured Wealth Private Client Group LLC Has $605,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Measured Wealth Private Client Group LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 45.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 16,849 shares of the biopharmaceutical company’s stock after selling 14,229 shares during the quarter. Measured Wealth Private Client Group LLC’s holdings in Pfizer were worth $605,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Evolution Wealth Advisors LLC acquired a new stake in shares of Pfizer in the 2nd quarter valued at approximately $34,000. IMA Wealth Inc. boosted its holdings in shares of Pfizer by 144.5% in the 2nd quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 477 shares during the last quarter. Financial Gravity Wealth Inc. boosted its holdings in shares of Pfizer by 33.2% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 257 shares during the last quarter. Vestor Capital LLC boosted its holdings in shares of Pfizer by 60.1% in the 2nd quarter. Vestor Capital LLC now owns 1,547 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 581 shares during the last quarter. Finally, Global Trust Asset Management LLC boosted its holdings in shares of Pfizer by 346.4% in the 2nd quarter. Global Trust Asset Management LLC now owns 7,758 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 6,020 shares during the last quarter. 71.69% of the stock is owned by hedge funds and other institutional investors.

PFE traded up $0.73 during trading hours on Friday, reaching $36.53. The company’s stock had a trading volume of 5,227,262 shares, compared to its average volume of 19,407,336. Pfizer Inc. has a 52 week low of $33.97 and a 52 week high of $46.47. The company’s 50-day moving average is $35.94 and its 200-day moving average is $39.97. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. The firm has a market cap of $195.97 billion, a PE ratio of 12.18, a price-to-earnings-growth ratio of 2.82 and a beta of 0.66.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.05. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The business had revenue of $13.26 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the prior year, the business earned $0.77 EPS. The firm’s revenue for the quarter was down 1.5% on a year-over-year basis. Equities analysts anticipate that Pfizer Inc. will post 2.81 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a yield of 3.94%. The ex-dividend date of this dividend is Thursday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

Several research firms have recently commented on PFE. Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price objective for the company in a report on Tuesday, October 1st. Credit Suisse Group reissued a “neutral” rating on shares of Pfizer in a report on Monday, August 12th. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. JPMorgan Chase & Co. increased their price objective on Pfizer from $37.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday, September 19th. They noted that the move was a valuation call. Finally, Morgan Stanley cut their price objective on Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a report on Tuesday, August 27th. Twelve analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $45.20.

In other news, major shareholder Pfizer Inc acquired 50,000 shares of the stock in a transaction on Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $900,000.00. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Scott Gottlieb acquired 3,000 shares of the stock in a transaction on Friday, August 23rd. The shares were purchased at an average price of $34.72 per share, for a total transaction of $104,160.00. Following the transaction, the director now directly owns 3,000 shares in the company, valued at $104,160. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: Intrinsic Value

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit